Literature DB >> 21371702

[Mortality risk factors for bloodstream infections caused by extended-spectrum beta-lactamase-producing microorganisms].

O Ferrández1, S Grau, P Saballs, S Luque, R Terradas, E Salas.   

Abstract

OBJECTIVE: To identify risk factors for mortality in patients with bloodstream infection by extended-spectrum beta-lactamase (ESBL)-producing microorganisms.
MATERIAL AND METHODS: A retrospective study in patients with bloodstream infection by ESBL-producing microorganisms from January 2000 to December 2006 was carried out.
RESULTS: A total of 4,172 bloodstream infections were identified, 1,218 (29.2%) and 226 (5.4%) of which were caused by Escherichia coli and Klebsiella pneumoniae, respectively. The overall mortality rate was 50.9% in patients with bacteriema due to ESBL-producing strains. The binomial logistic regression model, adjusted for age and severity, identified admission to an intensive care unit (OR 38,631; 95%CI:3,375-424,618; P=.002) and a SAPS II severity index score >30 in the 24-48 h before obtaining blood culture (OR 17,980; 95% CI:2,193-170,439; P=.010) as factors associated to mortality, while the urinary tract as primary site of infection was an independent determinant for non-mortality (OR 0.184; 95% CI:0.034-0.975; P=.047).
CONCLUSIONS: Patients with suspicion of bacteriema who have been admitted to the ICU with a score of elevated severity should be candidates for early empirical treatments as they have a greater risk of mortality. However, the benefit of this strategy may be limited due to the baseline severity of the patient.
Copyright © 2011 Elsevier España, S.L. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21371702     DOI: 10.1016/j.rce.2010.05.027

Source DB:  PubMed          Journal:  Rev Clin Esp        ISSN: 0014-2565            Impact factor:   1.556


  2 in total

1.  Clinical usefulness of the 2010 clinical and laboratory standards institute revised breakpoints for cephalosporin use in the treatment of bacteremia caused by Escherichia coli or Klebsiella spp.

Authors:  Nam Su Ku; Hae-Sun Chung; Jun Yong Choi; Dongeun Yong; Kyungwon Lee; June Myung Kim; Yunsop Chong
Journal:  Biomed Res Int       Date:  2015-02-22       Impact factor: 3.411

Review 2.  Piperacillin-tazobactam as alternative to carbapenems for ICU patients.

Authors:  Benoit Pilmis; Vincent Jullien; Alexis Tabah; Jean-Ralph Zahar; Christian Brun-Buisson
Journal:  Ann Intensive Care       Date:  2017-11-10       Impact factor: 6.925

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.